PL358253A1 - Sposób wytwarzania krystalicznej formy I kabergoliny - Google Patents

Sposób wytwarzania krystalicznej formy I kabergoliny

Info

Publication number
PL358253A1
PL358253A1 PL01358253A PL35825301A PL358253A1 PL 358253 A1 PL358253 A1 PL 358253A1 PL 01358253 A PL01358253 A PL 01358253A PL 35825301 A PL35825301 A PL 35825301A PL 358253 A1 PL358253 A1 PL 358253A1
Authority
PL
Poland
Prior art keywords
cabergoline
crystalline form
preparing crystalline
preparing
crystalline
Prior art date
Application number
PL01358253A
Other languages
English (en)
Inventor
Attilio Tomasi
Stefania Magenes
Mario Ungari
Giuliano Ramella
Gianfranco Pallanza
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL358253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Publication of PL358253A1 publication Critical patent/PL358253A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL01358253A 2000-03-24 2001-03-19 Sposób wytwarzania krystalicznej formy I kabergoliny PL358253A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (1)

Publication Number Publication Date
PL358253A1 true PL358253A1 (pl) 2004-08-09

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01358253A PL358253A1 (pl) 2000-03-24 2001-03-19 Sposób wytwarzania krystalicznej formy I kabergoliny

Country Status (31)

Country Link
US (2) US6727363B2 (pl)
EP (1) EP1272489B1 (pl)
JP (1) JP4184666B2 (pl)
KR (1) KR100827558B1 (pl)
CN (1) CN1188412C (pl)
AR (1) AR032449A1 (pl)
AT (1) ATE250601T1 (pl)
AU (2) AU780747B2 (pl)
BR (1) BR0109507A (pl)
CA (1) CA2402836A1 (pl)
CZ (1) CZ20023176A3 (pl)
DE (1) DE60100858T2 (pl)
DK (1) DK1272489T3 (pl)
EA (1) EA005928B1 (pl)
EE (1) EE05088B1 (pl)
ES (1) ES2208602T3 (pl)
GB (1) GB0007308D0 (pl)
HK (1) HK1052348B (pl)
HU (1) HUP0300591A3 (pl)
IL (2) IL150985A0 (pl)
MX (1) MXPA02009283A (pl)
MY (1) MY134189A (pl)
NO (1) NO20024321D0 (pl)
NZ (1) NZ521316A (pl)
PE (1) PE20011140A1 (pl)
PL (1) PL358253A1 (pl)
PT (1) PT1272489E (pl)
SI (1) SI1272489T1 (pl)
SK (1) SK13582002A3 (pl)
WO (1) WO2001070740A1 (pl)
ZA (1) ZA200206045B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2479140A1 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
BR0308472A (pt) * 2002-03-15 2005-01-11 Pharmacia Corp Processo para preparar a forma i cristalina de cabergolina
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
WO2004101510A2 (en) * 2003-05-08 2004-11-25 Ivax Corporation Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
WO2009027086A2 (en) * 2007-08-29 2009-03-05 Max Zeller Söhne Ag Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
WO1995005176A1 (en) 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
CN1303286A (zh) 1998-03-27 2001-07-11 法玛西雅厄普约翰美国公司 卡麦角林在治疗多动腿综合征中的应用
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Also Published As

Publication number Publication date
KR100827558B1 (ko) 2008-05-07
AU6211001A (en) 2001-10-03
SI1272489T1 (en) 2004-02-29
JP4184666B2 (ja) 2008-11-19
EE200200545A (et) 2004-04-15
DE60100858D1 (de) 2003-10-30
ATE250601T1 (de) 2003-10-15
JP2003528100A (ja) 2003-09-24
CN1188412C (zh) 2005-02-09
DK1272489T3 (da) 2003-12-15
EA200201016A1 (ru) 2003-02-27
WO2001070740A1 (en) 2001-09-27
US20040092744A1 (en) 2004-05-13
EP1272489B1 (en) 2003-09-24
US20030149067A1 (en) 2003-08-07
KR20020081587A (ko) 2002-10-28
AU2005203071B2 (en) 2007-10-18
AU2005203071A1 (en) 2005-08-11
DE60100858T2 (de) 2004-07-29
HUP0300591A2 (hu) 2003-07-28
HK1052348B (zh) 2005-09-16
NO20024321L (no) 2002-09-10
IL150985A0 (en) 2003-02-12
SK13582002A3 (sk) 2003-04-01
ES2208602T3 (es) 2004-06-16
CN1419554A (zh) 2003-05-21
NO20024321D0 (no) 2002-09-10
IL150985A (en) 2007-03-08
NZ521316A (en) 2004-05-28
US6727363B2 (en) 2004-04-27
HUP0300591A3 (en) 2009-01-28
AU780747B2 (en) 2005-04-14
GB0007308D0 (en) 2000-05-17
ZA200206045B (en) 2003-07-29
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
PT1272489E (pt) 2004-02-27
EE05088B1 (et) 2008-10-15
MY134189A (en) 2007-11-30
MXPA02009283A (es) 2003-03-12
EP1272489A1 (en) 2003-01-08
HK1052348A1 (en) 2003-09-11
EA005928B1 (ru) 2005-08-25
US6953854B2 (en) 2005-10-11
AR032449A1 (es) 2003-11-12
PE20011140A1 (es) 2001-11-01
CZ20023176A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
IL150985A0 (en) Process for preparing crystalline form i of cabergoline
EP1425279A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES
EP1331233A4 (en) METHOD FOR PRODUCING A POLYISOCYANATE COMPOSITION
EG23819A (en) Method for preparing of l-phenylephrine-hydrochloride
HUP0202097A2 (en) Process for preparing substituted cyclopentane derivatives and novel crystalline form of these derivatives
GB0016002D0 (en) Novel process for preparing crystalline particles
GB0007307D0 (en) Crystalline form || of cabergoline
SG99351A1 (en) Process for the manufacture of a crystalline solid
HUP0300160A3 (en) Process for preparing (+)-cis-sertraline
GB0007309D0 (en) Crystalline form V|| of cabergoline
IL163520A0 (en) Process for preparing crystalline form i of cabergoline
HUP0303907A3 (en) Improved process for preparation of steroids
IL163779A0 (en) Process for preparing crystalline form i of cabergoline
HUP0101875A3 (en) Process for the preparation of piperidine derivatives
HUP0303832A3 (en) Process for preparation of baccatin iii derivatives
HU0101722D0 (en) Process for producing of chocolate
HUP0203364A3 (en) Method for preparation of 3-substituted-4-arylquinolin-2-one derivatives
AU2001289303A1 (en) Process for producing crystalline tagatose
IL151632A0 (en) Process for preparing pure crystalline lorazepam
HU0104563D0 (en) Process for producing of food-enzymes
HUP0001408A2 (hu) Eljárás takarmánymagok előállítására
HUP0004469A3 (en) Process for producing trifluormethyl-aniline derivatives
HUP0000208A3 (en) Process for producing secondary-alkoxy-1-alkene derivatives
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
GB0016016D0 (en) Novel process for preparing crystalline particles

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)